Skip to main content

Table 3 Tumor response by RET fusion status

From: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

  RET+ cohort
(N = 46)
RET- cohort (N = 5761) p-value*
Any first-line therapy, unadjusted n (%)a n (%)a  
 Complete response (CR) 1 (3.7) 112 (4.7) 0.17
 Partial response (PR) 20 (74.1) 1284 (53.9)  
 Stable disease (SD) 2 (7.4) 530 (22.3)  
 Progressive Disease (PD) 4 (14.8) 455 (19.1)  
 Missing/unknown 19 3380  
First-line pembro + PC (KN-189 regimen), unadjusted N = 9 N = 665  
 CR 1 (12.5) 15 (3.4) 0.15
 PR 5 (62.5) 249 (57.1)  
 SD 0 (0.0) 100 (22.9)  
 PD 2 (25.0) 72 (16.5)  
 Missing/unknown 1 229  
Any second-line therapy, unadjusted N = 23 N = 3173  
 CR 0 (0.0) 47 (2.9) 0.93
 PR 6 (42.9) 564 (35.1)  
 SD 4 (28.6) 478 (29.7)  
 PD 4 (28.6) 519 (32.3)  
 Missing/unknown 9 1565  
Objective response rate (ORR) Odds ratio (95% confidence interval) p-value
 First line, unadjusted, n = 2408 2.47 (0.99, 6.14) 0.05
 First-line pembro +PC , unadjusted, n = 444 1.95 (0.39, 9.80) 0.49
 First line, adjustedb, n = 2408 0.44 (0.17, 1.13) 0.09
 First line pembro + PC, adjustedb, n = 444 0.63 (0.10, 3.84) 0.61
 Second line, unadjusted, n = 1622 1.22 (0.42, 3.54) 0.78
 Second line, adjustedb, n = 1622 0.58 (0.18, 1.87) 0.36
  1. * Fishers exact test; missing values not included in statistical calculations
  2. aDenominator for percentages excludes missing
  3. bMulitvariable adjusted logistic regression
  4. KN-189 first-line treatment with pembrolizumab (pembro) + pemetrexed + platinum (PC)
\